Curious about CAR T-cell therapy? We went straight to the source for answers.

In this episode, the LLS Patient Education team visited The University of Miami Sylvester Cancer Center to meet with Dr. Trent Wang. He answered some of the most frequently asked questions from our patients and caregivers about this innovative cancer treatment – from who’s eligible and what to expect, to side effects, caregiver roles, and exciting future developments.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Bristol Myers Squibb; Johnson & Johnson & Legend Biotech; and Kite, a Gilead Company.

The post CAR T-cell Therapy: Your Questions Answered first appeared on The Bloodline With Blood Cancer United Podcast.

Acute myeloid leukemia (AML) is one of the most aggressive blood cancers—but science is making real progress. In this episode, Dr. Eytan Stein of Memorial Sloan Kettering breaks down what makes AML so challenging to treat, how it’s classified, and the latest therapies changing the outlook for patients. From combination therapies and menin inhibitors to future research on CAR T-cell therapy and bispecifics, this is a hopeful, expert-led look at the future of AML treatment.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Abbvie Inc.; Astellas Pharma US Inc.; Genentech, A Member of the Roche Group; and Kura Oncology, Inc.

The post Understanding AML: The Challenges, The Progress, The Hope first appeared on The Bloodline With Blood Cancer United Podcast.

In this episode, we sit down with Dr. Cesar Rodriguez of Mount Sinai Hospital in New York, NY to discuss the evolving landscape of myeloma treatment. Groundbreaking innovations are bringing new hope to patients and caregivers. Dr. Rodriguez breaks down the latest advancements in immunotherapy, including CAR T-cell therapy and bispecific antibodies. Hear how researchers and physicians are working to make myeloma into a manageable, long-term disease, while ultimately searching for a cure.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Abbvie Inc.; Genentech, A Member of the Roche Group; and Johnson & Johnson.

The post Hope in Myeloma: The Road to Long-Term Survival first appeared on The Bloodline With Blood Cancer United Podcast.

A Cutaneous T-cell Lymphoma (CTCL) diagnosis can raise many questions, from understanding symptoms to exploring treatment options.  In this episode, we talk to Dr. Francine Foss of Yale University to break down what CTCL is, how to manage side effects, and the latest advancements in treatment—including promising immunotherapies like CAR T-cell therapy and bispecific antibodies.  We also discuss the critical role of clinical trials in shaping the future of CTCL care.  

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Kyowa Kirin, Inc.

The post Cutaneous T-Cell Lymphoma (CTCL): From Diagnosis to Innovation first appeared on The Bloodline With Blood Cancer United Podcast.

In this episode, we sit down with Dr. Bilal Abid from University of Texas Health Science Center in Houston to discuss how healthcare disparities have an effect on cancer care — especially when it comes to cutting-edge treatments such as stem cell transplantations and CAR T-cell therapy. We discuss how race, socioeconomic status, education, and geographic location can determine a patient’s access to cancer care. With travel, insurance, and systemic barriers in the mix, we explore what patients can do to navigate these challenges, and how treatment centers and policymakers are contributing to ensure equitable access to care for all patients.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Genentech, A Member of the Roche Group.

The post Impact of Disparity: Navigating Treatment Equality in Cancer Care first appeared on The Bloodline With Blood Cancer United Podcast.

A stem cell transplant for blood cancer is just the beginning – what may come next for the patient can be a complex journey. In this episode, Dr. Alison Loren of the University of Pennsylvania discusses graft-vs-host disease (GVHD), a possible complication of transplantation – exploring the latest advancements in treatment and how patients and caregivers can navigate the challenges ahead.

Mentioned on this episode: 

Additional LLS Support Resources: 

The post Beyond the Transplant: Navigating Graft-vs-Host Disease (GVHD) first appeared on The Bloodline With Blood Cancer United Podcast.

Research continues to accelerate for myelodysplastic syndromes (MDS), giving hope to patients and their loved ones. In this episode, Dr. William Shomali of Stanford University dives into cutting-edge treatments for both low and high-risk MDS. Learn about the innovative therapies that are enhancing quality of life and explore the promising strides towards curative treatments. Don’t miss this inspiring conversation filled with valuable insights and hope for a brighter future.  

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by Geron Corporation and Taiho Oncology, Inc.

The post There’s Always Hope: Myelodysplastic Syndromes (MDS) first appeared on The Bloodline With Blood Cancer United Podcast.

Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma. Tune in as we chat with Dr. Yasmin Karimi from the University of Michigan about the latest breakthroughs in treatment, including combination therapies, CAR T-cell therapy and bispecific antibodies. Discover how these innovations are offering new hope and pathways to cures for patients.

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by Genmab US, Inc.

The post Emerging Therapies and Hope: Diffuse Large B-cell Lymphoma first appeared on The Bloodline With Blood Cancer United Podcast.

Chronic myelomonocytic leukemia (CMML) has been a challenging disease to tackle, historically treated with therapies meant for other conditions. But there’s a new wave of hope!

Join us as Dr. Eric Padron of Moffitt Cancer Center and Dr. Lee Greenberger of The Leukemia & Lymphoma Society unveil the groundbreaking new CMML Initiative, fueled by recent funding aimed at revolutionizing treatment. Discover how this initiative is paving the way for individualized therapies that promise to enhance the quality of life for CMML patients and bring us closer to a cure.

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode is provided by Taiho Oncology, Inc.

The post Advancing the Science: Chronic Myelomonocytic Leukemia (CMML) first appeared on The Bloodline With Blood Cancer United Podcast.

Explore the cutting-edge of oncology as we delve into the revolutionary world of CAR T-cell therapy, a more recent medical advancement in the fight against blood cancer.  

Join our conversation with Dr. Marco Davila of Roswell Park Comprehensive Cancer Center in Buffalo, NY, as he highlights the significant impact CAR T-cell therapy has made on treating various blood cancers. Dr. Davila discusses the current uses of this therapy and gives us a look at the ongoing clinical trials that are broadening the horizons of this innovative treatment. 

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by Bristol Myers Squibb; Johnson & Johnson & Legend Biotech; Kite, a Gilead Company; and Novartis Pharmaceuticals Corp.

The post Cellular Revolution: CAR T-cell Therapy first appeared on The Bloodline With Blood Cancer United Podcast.